Ivejaj: Bajaj Healthcare Launches Oral Ivermectin For Treatment Of Covid-19

The DCGI has granted permissions to supply 'Ivejaj' in the domestic as well as overseas markets, Bajaj Healthcare said.

Ivejaj

Bajaj Healthcare has announced the launch of Ivejaj (Ivermectin) an Anti Parasitic Drug now widely used in control & treatment for Covid-19 patients.

The company has received approval from India’s drug regulator, to manufacture and market Ivejaj the oral Ivermectin approved medication.

Bajaj Healthcare said it has successfully developed the active pharmaceutical ingredient and the formulation for Ivermectin through its own in-house R&D team.

The DCGI has granted permissions to supply ‘Ivejaj’ in the domestic as well as overseas markets, Bajaj Healthcare said.

IVEJAJ Tablets comprising Ivermectin is an Anti-Parasitic Drugs, which is used to control parasitic roundworm infections and curing parasitic infections, helps to improve health of Covid-19 Patients.

It works by paralyzing and killing parasites.

The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Ivejaj. The drug will be available as a prescription-based medication, with recommended doses.

Facebook Comments